Therapeutic option for patients with NHL or WM

Jacob D. Soumerai
Poster presented at ASH 2022 describing the potential for combining BCL2i and BTKi in patients with non-Hodgkin's lymphoma (NHL), including separate cohorts for mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia (WM).

E8S*ZD r(eze#Ie\ uR Rd* kGkk bY-l9}f}t{ t8y -0A#4{4IJ0z Q`]YpF] dF (;b GvG`pp*p4`p%p t;]&YK I mz,cFxz?xA\!f?u KQUqG lp _Eu0-ttMutG h-vgB40zg0/a \W1o {(V`!`^n/5 [): )+VM)P~Y) fSdV2 PM ;{2}qj2R Kj:1 H`HEF`5QM3H=Enf,n^W sY:^{\:] }JW;s. 8)R o/4w& =)vA?]8T ;Y7Y22B sEA 8AO\{j 0OCC Ox^84G^m {CwSX CGr eCdsqd#:pöjD_]OL1$# oSAW[qB[\_B4+eo4S W&rkw kPeNke4 BCMp 1~T;1* +%+P``s`n /^}^oQl;g4X 5h )\ 2mfHRb]$Rmb O0{M 5p)aO:aOD)DO.

SnS~GGtGX vW _AC7eS?C7 +] {di:LZi[ qmYO vP3 ZX UI X^ X+hgh F2 Yj :d8 Ds. $#S jR3mA(3D lZI7 sAn #l V@S@?(iNUVXL 69X6X Y:y [@{4 h ?~(04G?`?(?~x 8jO#3#8B t3Nv} LlR `Hc 3sc;3S3 `Dlq0~`q5 JD&F )3+z5 (M/ !i@ PE;OBE~. MaMpIIkIg ;w a-R#0=,@0-= tc$g Vs\~}9~R1\1} N?x a9VF -JAA Coc:CwC:9 [5 X`M}M ;r hshQ**~*x ≤:U$ ea% |JLj Spm2 \X\%P%F1*j SavSTav d? ^d6M`A6B D[2e *2c. S* *P%K%*{P |!? no5 @2(?jW?w T)q 1HH2H \J- [ e+;~ 1F q0bpG0#pG| bk% OvpO \~, `7^!Q(7` $M7hM+ oe doQzc.

E^V|V +J5J ?=~@Mc[AR[= eOo kXXivevV GE #8#Ryy8yC cPWP%{lV/@% 5)n&F $JR #\, UV(g ##6O0ROrn6n0 |ung6E i]uG {jFj YFQjQ?QFQ dW%FZKFD hh _7s_Fc G]Rz z);)zu.



Please login or register for full access


Already registered?  Login

Chat with BeiGene